Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:5:767-72.
doi: 10.2147/tcrm.s5776. Epub 2009 Sep 24.

Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease

Michael Beck  1
Affiliations

Alglucosidase alfa: Long term use in the treatment of patients with Pompe disease

Michael Beck. Ther Clin Risk Manag. 2009.

Abstract

Pompe disease is a lysosomal storage disorder characterized by muscle weakness and cardiomyopathy. It shows a broad variability regarding the clinical severity as well as the age of onset. In the past, two different recombinant enzyme preparations have been developed for the treatment of Pompe patients: alpha-glucosidase, produced in rabbit milk, and alpha-glucosidase, produced in Chinese hamster ovary (CHO) cell lines. The CHO enzyme received marketing approval in 2006 after it was proven to be effective in ameliorating muscle strength and improving heart function. The other has not been approved. The clinical efficacy of this enzyme preparation could be confirmed by several clinical trials in patients with different age of onset and disease severity. Enzyme replacement therapy, however, has its limitations due to unsatisfactory access of recombinant alpha-glucosidase to the muscle cells and due to the formation of antibodies. To overcome these therapeutic restraints, the development of a more effective enzyme preparation may become necessary.

Keywords: Pompe disease; acid maltase deficiency; alglucosidase alfa; alpha glucosidase; enzyme replacement therapy; glycogen storage disorder type II.

PubMed Disclaimer

References

    1. van den Hout HM, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe’s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332–340. - PubMed
    1. Umapathysivam K, Hopwood JJ, Meikle PJ. Correlation of acid alpha-glucosidase and glycogen content in skin fibroblasts with age of onset in Pompe disease. Clin Chim Acta. 2005;361:1–2. 191–198. - PubMed
    1. Kamphoven JH, de Ruiter MM, Winkel LP, et al. Hearing loss in infantile Pompe’s disease and determination of underlying pathology in the knockout mouse. Neurobiol Dis. 2004;16(1):14–20. - PubMed
    1. Kishnani PS, Howell RR. Pompe disease in infants and children. J Pediatr. 2004;144(5 Suppl):S35–S43. - PubMed
    1. Laforet P, Petiot P, Nicolino M, et al. Dilative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease. Neurology. 2008;70(22):2063–2066. - PubMed